4MAN

Bcl_2-Navitoclax Analog (with Indole) Complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.234 
  • R-Value Work: 0.213 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Souers, A.J.Leverson, J.D.Boghaert, E.R.Ackler, S.L.Catron, N.D.Chen, J.Dayton, B.D.Ding, H.Enschede, S.H.Fairbrother, W.J.Huang, D.C.Hymowitz, S.G.Jin, S.Khaw, S.L.Kovar, P.J.Lam, L.T.Lee, J.Maecker, H.L.Marsh, K.C.Mason, K.D.Mitten, M.J.Nimmer, P.M.Oleksijew, A.Park, C.H.Park, C.M.Phillips, D.C.Roberts, A.W.Sampath, D.Seymour, J.F.Smith, M.L.Sullivan, G.M.Tahir, S.K.Tse, C.Wendt, M.D.Xiao, Y.Xue, J.C.Zhang, H.Humerickhouse, R.A.Rosenberg, S.H.Elmore, S.W.

(2013) NAT.MED. (N.Y.) 19: 202-208

  • DOI: 10.1038/nm.3048
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells ...

    Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.


    Organizational Affiliation

    AbbVie Inc., North Chicago, Illinois, USA. andrew.souers@abbvie.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Apoptosis regulator Bcl-2
A, B
166Homo sapiensMutation(s): 0 
Gene Names: BCL2
Find proteins for P10415 (Homo sapiens)
Go to Gene View: BCL2
Go to UniProtKB:  P10415
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1Y1
Query on 1Y1

Download SDF File 
Download CCD File 
A, B
4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]biphenyl-2-yl}methyl)piperazin-1-yl]-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide
C48 H52 Cl N7 O8 S
OEPSXIVYHBPSCA-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.234 
  • R-Value Work: 0.213 
  • Space Group: P 43
Unit Cell:
Length (Å)Angle (°)
a = 71.375α = 90.00
b = 71.375β = 90.00
c = 101.492γ = 90.00
Software Package:
Software NamePurpose
MAR345data collection
AMoREphasing
HKL-2000data scaling
DENZOdata reduction
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2013-08-16 
  • Released Date: 2014-01-29 
  • Deposition Author(s): Park, C.H.
  • This entry supersedes: 4LXE

Revision History 

  • Version 1.0: 2014-01-29
    Type: Initial release
  • Version 1.1: 2017-08-02
    Type: Refinement description, Source and taxonomy
  • Version 1.2: 2017-11-15
    Type: Refinement description